

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
30 June 2005 (30.06.2005)

PCT

(10) International Publication Number
WO 2005/058345 A1

(51) International Patent Classification⁷: **A61K 38/18**,
31/198, 31/04, A61P 1/00

(21) International Application Number:
PCT/CA2004/002142

(22) International Filing Date:
16 December 2004 (16.12.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/529,574 16 December 2003 (16.12.2003) US

(71) Applicant (for all designated States except US): **UNI-
VERSITY TECHNOLOGIES INTERNATIONAL
INC.** [CA/CA]; #130, 3553-31 Street North West, Calgary,
Alberta T2L 2K7 (CA).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **HARDIN, James A.**
[CA/CA]; 5016 Vantage Cres. N.W., Calgary, Alberta T3A
1X7 (CA). **BURET, Andre Gerald** [CA/CA]; 4523-41
Street NW, Calgary, Alberta T3A 0N3 (CA).

(74) Agents: **ARNOLDO, MaryAnne** et al.; Suite 3000, 79
Wellington Street West, Box 270, TD Centre, Toronto, ON
M5K 1N2 (CA).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.


[Continued on next page]

(54) Title: A TREATMENT FOR NECROTIZING ENTEROCOLITIS

*** P < 0.001 vs. Control
+++ P < 0.001 vs. NEC
+ P < 0.05 vs. NEC

Control
NEC
Arg
EGF
EGF+Arg

Overall Clinical Evaluation



(57) **Abstract:** The invention provides compositions and methods for the treatment of necrotizing enterocolitis (NEC). A treatment of epidermal growth factor (EGF) receptor agonist and L-arginine, a bioequivalent thereof, or NO-donor showed efficacy against NEC. The invention also provides kits, unit doses and uses comprising epidermal growth factor (EGF) receptor agonist and L-arginine, a bioequivalent thereof, or NO-donor for the treatment of NEC.

WO 2005/058345 A1